Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy
Key facts
- Who runs it
- The First Affiliated Hospital of Air Force Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 5 people, planned
- Started
- 8 Dec 2025
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional
- Treatments tested
- All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
- Record updated
- 24 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Confirmed as primary membranous nephropathy (PMN) by renal biopsy
- Classified as moderate-risk or high-risk refractory membranous nephropathy (rMN)
- Moderate-risk rMN is defined as: eGFR ≥ 90 ml/min/1.73m² AND 24-hour urinary protein > 3.5g/d, with a reduction of no more than 50% within 6 months of receiving renin-angiotensin system inhibitor (RASi) therapy
- High-risk rMN is defined as meeting one of the following:; eGFR < 60 ml/min/1.73m² and/or persistent proteinuria > 8g/d for more than 6 months; Normal eGFR with proteinuria > 3.5g/d and ≤50% reduction after 6 months of RASi therapy, PLUS at least one of the following: Serum albumin < 25g/L; PLA2R antibody > 50 RU/mL; Urinary α1-microglobulin > 40 μg/min; Urinary IgG > 1 μg/min; Urinary β2-microglobulin > 250 mg/d; IgG/albumin clearance ratio > 0.20
- Diagnosis of rMN requires failure of adequate first-line immunosuppressive therapy (≥6 months of steroids+cyclophosphamide, CNI, or rituximab), defined by any of the following: persistent high-titer anti-PLA2R antibody; for antibody-negative patients, persistent nephrotic syndrome (protein >3.5g/d, albumin <30g/L); <50% reduction in proteinuria
- Age ≥ 18 years
- Adequate organ function, defined as:; Renal: eGFR ≥ 30 ml/min/1.73m²; Hepatic: ALT and AST ≤ 2.5 x ULN; Total bilirubin ≤ 1.5 x ULN; Cardiac: LVEF ≥ 50%; NYHA Class I or II; No significant arrhythmias requiring intervention; No major cardiovascular events within the past 6 months; Respiratory: SpO2 > 92% on room air
- Ability to understand and willingness to sign an Informed Consent Form
Who cannot take part
- Specific treatment history or plans, including:; Prior receipt of any cell therapy (e.g., MSCs, HSCT); Major surgery within 24 weeks before or planned within 24 weeks after enrollment; Planned kidney transplantation within 3 years; History of substance abuse
- Participation in another interventional clinical trial within 3 months prior to enrollment
- Secondary membranous nephropathy (e.g., due to SLE, malignancy, drugs, infection)
- Active infection requiring IV antibiotics, active tuberculosis, or positive viral serology indicating active infection, including:; HBV: HBsAg (+) and/or HBcAb (+) with detectable HBV DNA; HCV: HCV Ab (+) with detectable HCV RNA; HIV Ab (+); Active EBV or CMV infection (IgM+ or DNA above normal); Positive syphilis (Treponema pallidum) antibody (requires evaluation for active infection)
- History of malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or thyroid cancer
- Inability to understand the study or provide informed consent (e.g., severe dementia, mental illness)
- Any other condition deemed by the investigator to increase risk, interfere with assessment, or affect compliance
- Severe uncontrolled comorbidities, including:; Uncontrolled hypertension (persistent SBP > 160 mmHg or DBP > 100 mmHg); Uncontrolled diabetes (HbA1c > 8% or random glucose ≥11.1 mmol/L) or diabetic nephropathy; Symptomatic deep vein thrombosis or pulmonary embolism within the past 6 months; Active peptic ulcer or gastrointestinal bleeding within the past 6 months; Severe congenital or acquired immunodeficiency; Severe CNS diseases (e.g., catastrophic APS, uncontrolled epilepsy); End-stage organ failure not attributable to PMN
- Pregnant or lactating women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.
Read full original descriptionShow less
Prior to receiving CAR-T cell therapy, patients will undergo lymphodepletion chemotherapy with cyclophosphamide (fludarabine will be added if necessary). After prophylactic administration of antihistamines and acetaminophen, patients will be infused with CD19 CAR-T cells at a dose of 1×10⁶ cells/kg.
In the subsequent 2 weeks, patients will be hospitalized for monitoring of vital signs and adverse reactions. The planned follow-up duration of this study is 1 years.
The group in the trial
- To preliminarily evaluate the safety and efficacy of CD19 CAR-T in refractory membranous nephropathyOther group
Treatment: All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in the Treatment of Refractory Membranous Nephropathy
- Record updated
- 24 December 2025